Immuneering Corporation
NASDAQ: IMRX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Benjamin J. Zeskind
- Employees
- 54
- Headquarters
- Cambridge, United States
- IPO year
- 2021
- Market cap
- $167.0M
- Website
- https://immuneering.com
Loading IMRX…
Loading profile data…Frequently asked questions about IMRX
What does Immuneering Corporation (IMRX) do?
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, color...
Where does IMRX trade?
Immuneering Corporation (IMRX) trades on the NASDAQ Global Market.
What sector is IMRX in?
Immuneering Corporation (IMRX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Immuneering Corporation?
Benjamin J. Zeskind is the chief executive officer of Immuneering Corporation (IMRX).
Where is Immuneering Corporation headquartered?
Immuneering Corporation is headquartered in United States.
Does IMRX pay a dividend?
Immuneering Corporation (IMRX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IMRX go public?
Immuneering Corporation (IMRX) completed its initial public offering in 2021.